Aeterna Zentaris, Inc. AEZS
AEZS is gapping up this morning on the heels of some news. It’s been quite a few months since we last mentioned this stock. That was back in the fall, and we subsequently witnessed quite a surge from the stock after that.
Since then, so far in 2017 the stock has come down to record new annual lows, and recently has been making incremental increases off of that bottom. In light of today’s news, described below, we think it’s a good time to put AEZS back on a more intensive watch.
The company announced this morning, following a comprehensive review Phase 3 clinical data on Macrilen™ for the evaluation of growth hormone deficiency, that Macrilen™ demonstrated performance supportive of achieving registration with the FDA. The FDA has agreed to consider the Company’s conclusions during a Type A meeting, which is currently being scheduled. (>>View PR)
Zosano Pharma Corp. ZSAN
Speaking of fresh news plays, we also want to highlight the announcement coming from ZSAN this morning that presently has the stock gapping up in the premarket to the tune of 50%
This morning ZSAN reported that in its ZOTRIP pivotal efficacy study, the company’s M207 transdermal migraine therapy patch met both primary, as well as secondary endpoints. It certainly explains the premarket hoopla, and warrants our observation as we kick off a new trading week.
The chart also has some attractive features which we’ve pointed out on the snapshot below:
**SPECIAL REMINDER**
To wrap things up this morning, we want to leave our readers with a quick heads up on a big Tuesday coming up. We’ve got a special report coming out tomorrow prior to the opening bell. It could represent quite an opportunity, so tomorrow is definitely not the day to miss out on our premarket report!
Be sure to stay locked onto your email inboxes or BlueHorseshoeStocks.com tomorrow between 9:00 to 9:15AM, and lean on those refresh buttons!
Extended Watchlist:
MCIG, MYHI, ADVT, MJTK, QSIM, NK